Indication: Melanoma
Phase 2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy in Patients With Advanced Melanoma Who Have Previously Received anti-PD-[L]1 Therapy – ARTISTRY-6
Sub-indication: Dermatologic Malignancies
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: Alkermes, Inc
Email for more information: Derm-NCIResearch@nortonhealthcare.org
